Aidoc has expanded its partnership with Integral Diagnostics (IDX) across Australia and New Zealand for artificial intelligence (AI)-driven medical imaging.

This collaboration, which began four years ago, utilises Aidoc's aiOS platform to alert care teams and radiologists to critical findings in medical images, enhancing patient care quality and timeliness.

The platform is designed to automatically flag critical pathologies such as pulmonary embolisms, brain aneurysms, strokes, and brain bleeds.

In anticipation of the Australian Government's funding for the National Lung Cancer Screening Programme (NLCSP) starting July 2025, IDX is trialling a new algorithm within the aiOS platform.

This algorithm aims to notify radiologists of lung nodules and their measurements accurately and enable earlier intervention for lung cancer.

Integral Diagnostics CEO and managing director Dr Ian Kadish said: "Aidoc's AI has significantly improved patient care and service.

“We're keen to test and use their Chest CT AI algorithms to automate our reviews in the National Lung Cancer Screening Programme to enable us to detect disease earlier, more accurately and more efficiently."

Since 2019, over 600,000 cases have been processed across IDX's network, including partner facilities and hospitals.

The aiOS platform is already in use across the US and Europe, analysing more than three million patients every month and supported by over 150 published papers and abstracts.

Aidoc Business Development senior director Rotem Geslevich said: "Our partnership with Integral Diagnostics underscores our commitment to driving better health outcomes.

"As the Lung Cancer Screening initiative approaches, we are excited to play a pivotal role in saving lives."

Both companies will be showcased at the upcoming RANZCR conference taking place from 17 to 19 October 2024 in Perth.